A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.

References

• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Europe, WHO announces COVID-19 outbreak a pandemic. [ updated 2020 Mar 12; cited 2020 Mar 17]. Available from: http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic
   Google Scholar
• World Health Organization. Coronavirus disease 2019 (COVID-19), Situation Report. [ Updated 2020 Oct 2; cited 2020 Oct 6]. Available from: https://www.who.int/publications/m/item/weekly-update-on-covid-19—2-october-2020
   Google Scholar
• Center for Disease Control and Prevention (CDC). [ Updated 2020 Oct 6; cited 2020 Oct 6]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html
   Google Scholar
• Center for Disease Control and Prevention (CDC). Coronavirus disease 2019 (COVID-19), prevent getting sick. [ Updated 2020 Apr 11; cited 2020 Apr 11]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/social-distancing.html
   Google Scholar
• USFDA, Coronavirus Disease 2019 (COVID-19). [ Updated 2020 Apr 4; cited 2020 Apr 11]. Available from: https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19
   Google Scholar
• Nitulescu GM, Paunescu H, Moschos SA, et al. Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: mechanistic insights into current COVID‑19 therapies (Review). Int J Mol Med. 2020;46:467–488.
   PubMed Web of Science ®Google Scholar
• Alexander SPH, Armstrong JF, Davenport AP, et al. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR review 29. Br J Pharmacol. 2020 May 1;177:4942–4966. Epub ahead of print. PMID: 32358833; PMCID: PMC7267163.
   Web of Science ®Google Scholar
• Schlagenhauf P, Grobusch MP, Maier JD, et al. Repurposing antimalarials and other drugs for COVID-19. Travel Med Infect Dis. 2020 Mar;34:101658.
   PubMed Web of Science ®Google Scholar
• USFDA. Drugs@FDA: FDA-approved drugs. [ Updated 2020 Mar 19; cited 2020 Apr 11]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009768
   Google Scholar
• Gautret P, Lagier J, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949.
   Google Scholar
• USFDA. Coronavirus (COVID-19) update: FDA continues to facilitate development of treatments. [ Updated 2020 Mar 19; cited 2020 Apr 11]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-facilitate-development-treatments
   Google Scholar
• Chatre C, Roubille F, Vernhet H, et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41:919–931.
   PubMed Web of Science ®Google Scholar
• Sapp JL, Alqarawi W, MacIntyre CJ, et al. Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the Canadian heart rhythm society. Can J Cardiol. 2020;36:948–951.
   Web of Science ®Google Scholar
• Das S, Bhowmick S, Tiwari S, et al. An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease 19 (COVID 19). Clin Drug Investig. 2020;40:591–601.
   PubMed Web of Science ®Google Scholar
• Sachdeva C, Wadhwa A, Kumari A, et al. In silico potential of approved antimalarial drugs for repurposing against COVID-19. OMICS. 2020;24:568–580. https://www.liebertpub.com/doi/10.1089/OMI.2020.0071.
   PubMed Web of Science ®Google Scholar
• Gendrot M, Andreani J, Boxberger M, et al. Antimalarial drugs inhibit the replication of SARS-CoV-2: an in vitro evaluation. Travel Med Infect Dis. 2020;37:101873. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477610/.
   PubMed Web of Science ®Google Scholar
• Sarayani A, Cicali B, Henriksen C, et al. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res Social Adm Pharm. Published online 2020 Apr 19;S1551-7411(20)30391-0. doi:10.1016/j.sapharm.2020.04.016.Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Singh AP, Tousif S, Umbarkar P, et al. A pharmacovigilance study of hydroxychloroquine cardiac safety profile: potential implication in COVID-19 mitigation. J Clin Med. 2020;9(6):1867.
   PubMed Web of Science ®Google Scholar
• Sonawane KB, Cheng N, Hansen RA. Serious adverse drug events reported to the FDA: analysis of the FDA adverse event reporting system 2006–2014 database. JMCP. 2018;24:682–690.
   PubMed Web of Science ®Google Scholar
• USFDA. Questions, and answers on FDA’s adverse event reporting system (FAERS). [ Updated 2020 Apr 4; cited 2020 Apr 17]. Available from: https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers
   Google Scholar
• USFDA. FDA adverse event reporting system (FAERS) electronic submissions. [ Updated 2020 Mar 3; cited 2020 Apr 17]. Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-electronic-submission
   Google Scholar
• Böhm R, von Hehn L, Herdegen T, et al. OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS One. 2016 Jun 21;11(6):e0157753. PMID: 27326858; PMCID: PMC4915658.
   PubMed Web of Science ®Google Scholar
• Tripepi G, Jager KJ, Dekker F, et al. Stratification for confounding – part 1: the Mantel-Haenszel formula. Nephron Clin Pract. 2010;116:c317–c321.
   PubMedGoogle Scholar
• Rosenberg E, Dufort E, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in NewYork state. JAMA. Published online 2020 May 11;323:2493.
   PubMed Web of Science ®Google Scholar
• Mercuro N, Yen C, Shim D, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 May 1;e201834.
   Web of Science ®Google Scholar
• Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020 Sep;17(9):1425–1433. Epub 2020 May 12. PMID: 32407884; PMCID: PMC7214283.
   PubMed Web of Science ®Google Scholar
• Palleria C, Leporini C, Chimirri S, et al. Limitations and obstacles of the spontaneous adverse drug reactions reporting: two “challenging” case reports. JPP. 2013;4:S66.
   Google Scholar
• Montastruc JL, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905–908.
   PubMed Web of Science ®Google Scholar
• Faillie JL, Oriana HY, Yin H, et al. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176:1474–1481.
   PubMed Web of Science ®Google Scholar